We recently shared with the community the disappointing news about that Biogen have withdrawn their application to NICE (the body that makes decisions on reimbursement of medicines in the UK) for omaveloxolone to treat adults with Friedreich’s ataxia (FA).
As we understand how frustrating this news is for the FA community, Ataxia UK has written an open letter to the Secretary of State for Health and Social Care requesting interim access to the drug for FA patients in the UK.
Sign the letter here and share with your community.Â
